Summary
A total of 92 patients with previously untreated intermediate- or high-grade non-Hodgkin's lymphoma attending the University Department of Medicine, Queen Mary Hospital, Hong Kong, were treated with the m-BACOD chemotherapy regimen (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone). Additional involved-field radiotherapy was given to 32 (35%) patients. Myelosuppression was the major toxicity, and 5 (5%) treatment-related deaths occurred due to pneumonia, bleomycin sensitivity, doxorubicin cardiotoxicity and reactivation of hepatitis B infection. The overall complete response (CR) rate was 65/92 (71%) and the relapse rate was 22/65 (34%). The disease-free survival of the 65 CR patients at 2 years was 52% and the overall survival of all 92 patients at 3 years was 56%. The CR rate of stage I and II patients was significantly better than that of those with stage III and IV disease (87% vs 59%;P=0.01), and the CR rate of stage III patients was superior to that of those with stage IV disease (86% vs 50%;P=0.05). The overall survival of stage III and IV patients was significantly worse than that of subjects with stage I and II disease (31% vs 73%;P=0.02). Multivariate analysis revealed that the independent prognostic variables significantly determining the CR rate and survival included the clinical stage and the serum lactate dehydrogenase level. From this study, the results of treatment with the m-BACOD regimen in patients with advance disease appeared to be similar to those obtained using the conventional CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone).
Similar content being viewed by others
References
Armitage JO, Cheson BD (1988) Interpretation of clinical trials in diffuse large-cell lymphoma (editorial). J Clin Oncol 6: 1335–1347
Canellos GP, Skarin AT, Klatt MM, Rosenthal DS, Case DC Jr, Pinkus GS, Jochelson MS, Yeap BY, Shipp MA (1987) The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Semin Hematol 24 [Suppl 1]: 2–7
Carbone PP, Kaplan HS, Mushoff K, Smithiers DW, Tubiana M (1971) Report of the committee on Hodgkin's disease staging. Cancer Res 31: 1860–1861
Dahlberg, Miller TP, Dana B, Weick J, Fisher RI (1990) Dose intensity is not associated with subsequent survival after adjustment for known prognostic factors in non-Hodgkin's lymphoma patients treated with m-BACOD, ProMace-CytaBOM, and MACOP-B in Southwest Oncology Group studies. Proc Am Soc Clin Oncol 9: 986
Ho FCS, Loke SL, Hui PK, Todd D (1986) Immunohistological subtypes of non-Hodgkin's lymphoma in Hong Kong Chinese. Pathology 18: 426–430
Hoogstraten B (1984) Reporting treatment results in solid tumours. In: Buyse ME, Staquet MJ, Sylvester RJ (eds) Cancer clinical trials, methods and practice. Oxford University Press, Oxford, pp 139–156
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457–681
Liang R, Todd D, Chan TK, Wong KL, Ho F, Loke SL (1987) Peripheral T-cell lymphoma. J Clin Oncol 5: 750–755
Liang R, Chiu EKW, Chan TK, Todd D, Loke SL (1990) Management of advanced stage intermediate grade non-Hodgkin's lymphomas. Hematol Oncol 8: 147–154
Linch DC, Vaughan-Hudson B (1988) The management of Hodgkin's and non-Hodgkin's lymphoma. In: Hoffbrand AV (ed) Recent advances in haematology. Churchill Livingstone, Edinburgh, pp 211–242
McKelvey EM, Gottlieb JA, Wilson HE, Hant A, Talley RW, Stephens R, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE (1976) Hydroxyldaunorubicin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38: 1473–1484
Non-Hodgkin's Lymphoma Pathologic Classification Projects (1982) NCI-sponsored study of classifications of non-Hodgkin's lymphomas. Cancer 49: 2112–2135
Schein PS, De Vita VT Jr, Hubbard S, Chabner BA, Canellos GP, Berrard C, Young RC (1976) Bleomycin, Adriamycin, cyclophosphamide, vincristine and prednisone (BACOP) combination chemotherapy in the treatment of advance aggressive histiocytic lymphoma. Ann Intern Med 85: 417–422
Shipp MA, Harrington DP, Klatt MM, Jochelson MS, Pinkus GS, Marshall JL, Rosenthal DS, Skarin AT, Canellos GP (1986) Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 104: 757–765
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Liang, R., Chiu, E., Chan, T.K. et al. m-BACOD chemotherapy for intermediate- and high-grade non-Hodgkin's lymphoma. Cancer Chemother. Pharmacol. 28, 135–138 (1991). https://doi.org/10.1007/BF00689703
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00689703